Get the Stockscreener App
0.9363
0.68%
0.0063
Co Diagnostics Inc stock is traded at $0.9363, with a volume of 272.74K.
It is up +0.68% in the last 24 hours and down -23.88% over the past month.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
See More
Previous Close:
$0.93
Open:
$0.92
24h Volume:
272.74K
Relative Volume:
2.13
Market Cap:
$29.38M
Revenue:
$7.11M
Net Income/Loss:
$-41.28M
P/E Ratio:
-0.7551
EPS:
-1.24
Net Cash Flow:
$-26.84M
1W Performance:
-9.97%
1M Performance:
-23.88%
6M Performance:
-11.67%
1Y Performance:
-13.31%
1-Day Range:
$0.88
$0.9816
1-Week Range:
$0.88
$1.0799
52-Week Range:
$0.88
$2.2299
Co Diagnostics Inc Stock (CODX) Company Profile
Name
Co Diagnostics Inc
Sector
Industry
Phone
(801) 278-9769
Address
4049 SOUTH HIGHLAND DRIVE, SALT LAKE CITY
Compare CODX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CODX
Co Diagnostics Inc
|
0.9363 | 29.38M | 7.11M | -41.28M | -26.84M | -1.24 |
|
ABT
Abbott Laboratories
|
118.95 | 208.18B | 41.22B | 5.77B | 6.49B | 2.94 |
|
SYK
Stryker Corp
|
388.14 | 148.70B | 21.97B | 3.59B | 3.21B | 6.74 |
|
BSX
Boston Scientific Corp
|
90.75 | 133.32B | 15.91B | 1.79B | 1.89B | 0.82 |
|
MDT
Medtronic Plc
|
86.27 | 111.27B | 33.00B | 4.29B | 5.50B | 2.71 |
|
EW
Edwards Lifesciences Corp
|
72.07 | 42.66B | 6.60B | 4.16B | 490.10M | 2.34 |
Co Diagnostics Inc Stock (CODX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-22 | Downgrade | Sidoti | Buy → Neutral |
| Dec-29-21 | Initiated | Sidoti | Buy |
| Mar-29-21 | Downgrade | Maxim Group | Buy → Hold |
| May-20-20 | Upgrade | Maxim Group | Hold → Buy |
| May-18-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-09-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-03-20 | Downgrade | Maxim Group | Buy → Hold |
View All
Co Diagnostics Inc Stock (CODX) Latest News
Co-Diagnostics (HAM:C97) Cash Flow from Operations : €-23.54 Mil (TTM As of Sep. 2024) - GuruFocus.com
Co-Diagnostics (HAM:C97) Forward Rate of Return (Yacktman) % : 0.00% (As of Sep. 2024) - GuruFocus.com
Co-Diagnostics, Inc. to Accompany Utah Governor and WTC Utah on Trade Mission to South Korea and Japan - GuruFocus.com
CODX (Co-Diagnostics) 3-Year Book Growth Rate : 5.60% (As of Sep. 2024) - GuruFocus.com
CODX (Co-Diagnostics) Momentum Rank : 8 (As of Nov. 26, 2024) - GuruFocus.com
Co-Diagnostics, Inc. to Host Booth at the 2024 UHCA/UCAL Fall Convention & Expo on Oct 2-3 - GuruFocus.com
Co-Diagnostics stock hits 52-week low at $1 amid market challenges By Investing.com - Investing.com South Africa
Co-Diagnostics stock hits 52-week low at $1 amid market challenges - Investing.com Nigeria
CODX (Co-Diagnostics) 3-Year EPS without NRI Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com
Co-Diagnostics, Inc. Reports Third Quarter 2024 Financial Results - GuruFocus.com
Co-Diagnostics (LTS:0A50) Total Liabilities : $8.60 Mil (As of Sep. 2024) - GuruFocus.com
Daxor (NASDAQ:DXR) & Co-Diagnostics (NASDAQ:CODX) Critical Survey - Defense World
Co-Diagnostics, Inc. (CODX) Reports Q3 Loss, Tops Revenue Estimates - MSN
Co-Diagnostics Q3 2024 Earnings Preview - MSN
Co-Diagnostics Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
Co-Diagnostics, Inc. (NASDAQ:CODX) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Co-Diagnostics reports decreased Q3 revenue, eyes growth By Investing.com - Investing.com Australia
Co-Diagnostics Inc (CODX) Q3 2024 Earnings Call Highlights: Navi - GuruFocus.com
Co-Diagnostics Inc (CODX) Q3 2024 Earnings Call Highlights: Navigating Revenue Decline and ... - Yahoo Finance
Co-Diagnostics Reports Q3 2024 Financial Results - TipRanks
Co-Diagnostics earnings beat by $0.01, revenue topped estimates - Investing.com UK
CODX (Co-Diagnostics) GF Value Rank : 0 (As of Nov. 05, 2024) - GuruFocus.com
Co-Diagnostics, Inc. to Host Booth at MEDICA Trade Fair in Düsseldorf, Germany on Nov 11-14, 2024 - PR Newswire
Co-Diagnostics to Showcase PCR Innovation at World's Largest Medical Trade Fair MEDICA 2024 | CODX Stock News - StockTitan
Analyzing Insulet (NASDAQ:PODD) and Co-Diagnostics (NASDAQ:CODX) - Defense World
Co-Diagnostics, Inc. Announces Third Quarter 2024 Earnings Relea - GuruFocus.com
Is Co-Diagnostics (NASDAQ:CODX) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Co-Diagnostics, Inc. Announces Third Quarter 2024 Earnings Release Date and Webcast - BioSpace
Infectious Disease Diagnostics Market to Reach USD 43.09 Billion by 2031 | SkyQuest Technology - Benzinga
Co-Diagnostics, Inc. to Host Booth at Medlab Africa in Cape Town on Oct 22-24, 2024 - PR Newswire
Some of the Key Players in the Emerging Infectious Disease Diagnostics Market : - InsightAce Analytic
Co-Diagnostics Inc (CODX) Q2 2024 Earnings Call Highlights: Revenue Surge Amidst Regulatory Hurdles - Yahoo Finance
The APAC Coronavirus Test Kits Market is projected to grow by USD 2.87 Billion (2024-2028), driven by increased availability of test kits and AI-powered market evolutionTechnavio - Lelezard
In-vitro Diagnostics Kit Market is Expected to See a Growth of 4.40% CAGR from 2024 to 2034 | Future Market Insights, Inc. – Market Research Blog - Market Research Blog
Coronavirus Test Kits Market in North America to Shrink by USD 1.41 Billion (2024-2028) as Integration with Routine Healthcare Evolves, AI-Powered Report by Technavio - The Malaysian Reserve
Co-Diagnostics, Inc. (NASDAQ:CODX) Short Interest Down 30.9% in September - Defense World
Co-Diagnostics (CODX) Price Target Increased by 50.00% to 3.06 - MSN
Co-Diagnostics Inc Inc. (CODX) Price Performance: A Comparative Analysis with Competitors - The InvestChronicle
Co-Diagnostics' Mpox test effective against new clade - Investing.com
Co-Diagnostics completes updated clade Ib analysis of 2-Gene Mpox RUO test - TipRanks
Co-Diagnostics, Inc. Completes Updated Clade Ib Analysis of 2-Gene Mpox RUO Test - PR Newswire
Multiplex Assay Market to Soar USD 6.75 Bn by 2034: Projections Show 4x Growth Driven by Innovations in Diagnostics and Drug Discovery - BioSpace
How does Co-Diagnostics Inc (CODX) change from a tortoise to a hare? - SETE News
Balance Sheet Insights: Co-Diagnostics Inc (CODX)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Co-Diagnostics Inc (CODX) shows promising results - US Post News
Co-Diagnostics sees shareholder backing in annual meeting votes By Investing.com - Investing.com South Africa
Co-Diagnostics sees shareholder backing in annual meeting votes - Investing.com
Closing Bell Recap: Co-Diagnostics Inc (CODX) Ends at 1.58, Reflecting a -9.71 Downturn - The Dwinnex
Co-Diagnostics Inc (CODX) presents a great opportunity, but the stock is slightly undervalued - US Post News
Are Medical Stocks Lagging Context Therapeutics Inc. (CNTX) This Year? - Yahoo Finance
Co Diagnostics Inc Stock (CODX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):